KU
KUR.F Kura Oncology Inc
- Market cap
- EUR 606M
- P/E
- -
- P/B
- 40.57x
- ROE
- -1,572.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KUR.F undervalued?
Graham numberThe Graham number of Kura Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kura Oncology Inc fundamental analysis
No fundamental analysis for Kura Oncology Inc yet.
Kura Oncology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibi…
Full company profileKura Oncology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kura Oncology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53.9M | 67.5M | 82.6M |
| Gross Profit | - | - | - | - | - | - | - | 0.00 | 53.9M | 67.4M | 81.5M |
| Operating Income | -28.4M | -36.1M | -62.9M | -67.5M | -91.9M | -131M | -140M | -166M | -193M | -304M | -302M |
| EBITDA | - | -34.5M | -59.5M | -62.6M | -88.9M | -129M | -135M | -150M | -169M | -276M | -280M |
| Net Income | -27.6M | -35.4M | -60.4M | -63.1M | -89.6M | -130M | -136M | -153M | -174M | -279M | -283M |
| EPS | - | -1.17 | -1.58 | -1.39 | -1.35 | -1.96 | -1.99 | -2.05 | -2.22 | -3.17 | -3.07 |
| Balance Sheet | |||||||||||
| Total Assets | 69.8M | 95.9M | 182M | 242M | 647M | 534M | 456M | 449M | 760M | 738M | 566M |
| Total Liabilities | 12.9M | 16.0M | 21.4M | 23.2M | 36.3M | 27.4M | 36.0M | 51.7M | 347M | 564M | 549M |
| Shareholders' Equity | 56.9M | 79.9M | 161M | 219M | 611M | 507M | -569M | 397M | 414M | 174M | 18.0M |
| Cash & Short-term Investments | 9.73M | 11.4M | 16.1M | 26.1M | 325M | 90.7M | 51.8M | 37.3M | 224M | 149M | 57.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -25.3M | -28.4M | -48.7M | -54.8M | -69.8M | -105M | -110M | -125M | 134M | -64.1M | -270M |
| Capital Expenditure | 0.00 | 2.17M | 2.17M | 2.17M | 2.17M | 1.15M | 626K | 168K | 472K | 6.64M | 1.64M |
| Free Cash Flow | - | -28.4M | -48.7M | -54.8M | -72.0M | -106M | -111M | -125M | 134M | -70.7M | -272M |
| Ratios | |||||||||||
| ROE | -48.5% | -44.4% | -37.5% | -28.9% | -14.7% | -25.8% | - | -38.4% | -42.1% | -160.0% | -1,572.9% |
| ROA | -39.5% | -37.0% | -33.1% | -26.1% | -13.8% | -24.4% | -29.8% | -34.0% | -22.9% | -37.7% | -49.9% |
| Net Profit Margin | - | - | - | - | - | - | - | - | -322.9% | -412.9% | -341.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kura Oncology Inc dividends
Kura Oncology Inc has not paid dividends in the last 9 fiscal years.
Who owns Kura Oncology Inc
- Insiders 1.35%
- Institutions 98.65%
- Public & others 0.00%
- Shares outstanding 91.9M
- Free float 72.8M
Kura Oncology Inc company profile
- Company name
- Kura Oncology Inc
- Ticker
- KUR.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 260
- Fiscal year end
- December
- Address
- 4930 Directors Place, San Diego, CA, United States, 92121
- Phone
- 858 500 8800
- Website
- kuraoncology.com
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology Inc management
10- Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO & President · born 1969
- Ms. Kathleen FordChief Operating Officer · born 1947
- Mr. Brian T. Powl M.B.A., M.S.Chief Commercial Officer · born 1974
- Ms. Jennifer FulkChief Financial Officer · born 1977
- Mr. Thomas DoyleSenior Vice President of Finance & Accounting · born 1971
- Dr. Francis J. Burrows Ph.D.Chief Scientific Officer · born 1962
- Mr. Greg MannSenior Vice President of Investor Relations & Corporate Affairs
- Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply Chain
- Dr. Mollie Leoni M.D.Chief Medical Officer · born 1978